Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection.

1988 ◽  
Vol 6 (11) ◽  
pp. 1722-1727 ◽  
Author(s):  
W J Curran ◽  
M J Kornstein ◽  
J J Brooks ◽  
A T Turrisi

To evaluate the role of mediastinal irradiation (RT) following surgery for invasive thymomas, a clinical and pathologic review of 117 patients with the diagnosis of thymoma was completed. Fourteen cases were excluded because of the lack of histologic criteria for a thymic tumor, and the remaining 103 were classified according to a staging system as follows: stage I, completely encapsulated (43); stage II, extension through the capsule or pericapsular fat invasion (21); stage III, invasion of adjacent structures (36); and stage IV, thoracic dissemination or metastases (3). The 5-year actuarial survival and relapse-free survival rates were 67% and 100% for stage I, 86% and 58% for stage II, and 69% and 53% for stage III. No recurrences occurred among stage I patients after total resection without RT. However, eight of 21 patients with invasive (stage II or III) thymomas had mediastinal recurrence as the first site of failure following total resection without RT. The 5-year actuarial mediastinal relapse rate of 53% in this group compares unfavorably with the mediastinal relapse rate seen among stage II or III cases following total resection with RT (0%) or following subtotal resection/biopsy with RT (21%). Despite attempted salvage therapy, five of eight patients with mediastinal relapse following total resection alone died of progressive disease. No significant difference was observed in the local relapse rate, overall relapse rate, or survival between those patients undergoing biopsy and RT v subtotal resection and RT for invasive thymomas (stages II and III). Total resection alone appears to be inadequate therapy resulting in an unacceptably high local failure rate with poor salvage therapy results.

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Milani ◽  
L Obici ◽  
R Mussinelli ◽  
M Basset ◽  
G Manfrinato ◽  
...  

Abstract Background Cardiac wild type transthyretin (ATTRwt) amyloidosis, formerly known as senile systemic amyloidosis, is an increasingly recognized, progressive, and fatal cardiomyopathy. Two biomarkers staging systems were proposed based on NT-proBNP (in both cases) and troponin or estimated glomerular filtration rate, that are able to predict survival in this population. The availability of novel effective treatments requires large studies to describe the natural history of the disease in different populations. Objective To describe the natural history of the disease in a large, prospective, national series. Methods Starting in 2007, we protocolized data collection in all the patients diagnosed at our center (n=400 up to 7/2019). Results The referrals to our center increased over time: 5 cases (1%) between 2007–2009, 33 (9%) in 2010–2012, 90 (22%) in 2013–2015 and 272 (68%) in 2016–2019. Median age was 76 years [interquartile range (IQR): 71–80 years] and 372 patients (93%) were males. One hundred and seventy-three (43%) had atrial fibrillation, 63 (15%) had a history of ischemic cardiomyopathy and 64 (15%) underwent pacemaker or ICD implantation. NYHA class was I in 58 subjects (16%), II in 225 (63%) and III in 74 (21%). Median NT-proBNP was 3064 ng/L (IQR: 1817–5579 ng/L), troponin I 0.096 ng/mL (IQR: 0.063–0.158 ng/mL), eGFR 62 mL/min (IQR: 50–78 mL/min). Median IVS was 17 mm (IQR: 15–19 mm), PW 16 mm (IQR: 14–18 mm) and EF 53% (IQR: 45–57%). One-hundred and forty-eight subjects (37%) had a concomitant monoclonal component in serum and/or urine and/or an abnormal free light chain ratio. In these patients, the diagnosis was confirmed by immunoelectron microscopy or mass spectrometry. In 252 (63%) the diagnosis was based on bone scintigraphy. DNA analysis for amyloidogenic mutations in transthyretin and apolipoprotein A-I genes was negative in all subjects. The median survival of the whole cohort was 59 months. The Mayo Clinic staging based on NT-proBNP (cutoff: 3000 ng/L) and troponin I (cutoff: 0.1 ng/mL) discriminated 3 different groups [stage I: 131 (35%), stage II: 123 (32%) and stage III: 127 (33%)] with different survival between stage I and II (median 86 vs. 81 months, P=0.04) and between stage II and III (median 81 vs. 62 months, P<0.001). The UK staging system (NT-proBNP 3000 ng/L and eGFR 45 mL/min), discriminated three groups [stage I: 170 (45%), stage II: 165 (43%) and stage III: 45 (12%)] with a significant difference in survival: between stage I and stage II (86 vs. 52 months, P<0.001) and between stage II and stage III (median survival 52 vs. 33 months, P=0.045). Conclusions This is one of the largest series of patients with cardiac ATTRwt reported so far. Referrals and diagnoses increased exponentially in recent years, One-third of patients has a concomitant monoclonal gammopathy and needed tissue typing. Both the current staging systems offered good discrimination of staging and were validated in our independent cohort. Funding Acknowledgement Type of funding source: None


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5074-5074
Author(s):  
Argyro Papadogiannis ◽  
Marie-Cristine Kyrtsonis ◽  
Theodoros P. Vassilakopoulos ◽  
Tatiana Tzenou ◽  
Antonios G. Antoniadis ◽  
...  

Abstract Cytokines, such as MIP-1a (macrophage inhibiting factor) and OPG (osteoprotegerin) are assumed to play a role in MM disease biology and bone disease, by mechanisms that are still under investigation. MIP-1a is constitutively secreted by myeloma cells, plays a possible role in the development of MM bone lesions, enhance MM cell adhesion to stromal cells and its serum levels have been recently related to survival in MM. OPG is a soluble decoy receptor which acts as a soluble receptor antagonist that prevents osteoclasts activation and the development of bone disease. Reported findings on serum OPG levels in MM patients are controversial as well as its possible role in the biology of the disease. In order to investigate the possible relationship of MIP-1a and OPG levels in MM patients with prognosis and bone disease, we determined by ELISA serum MIP-1a and OPG levels in 20 MGUS, 82 MM patients and 27 healthy individuals (HI). Both cytokines were determined by ELISA (R&D, Quantikine, USA) in frozen sera collected at dignosis, before treatment. The median age of MM patients was 69 years (44–84) and 50% were males. MM patients’ stage was as follows: 23 stage I, 28 stage II, 31 stage III according to Durie-Salmon staging system and 27 stage I, 17 stage II, 35 stage III according to the International Scoring System (ISS). In HI median MIP-1a was 28 pg/ml (15–54) and median OPG 1600 pg/ml (450–4600). In subjects with MGUS, median MIP-1a was 34 pg/ml (17–58) and median OPG 2300 pg/ml (820–6200). In MM patients, median pretreatment serum MIP-1a was 32 pg/ml (16–100) and OPG 3000 pg/ml (820–25000). No statistical significant difference was observed between HI, MGUS and MM patients with regard to MIP-1a levels but for OPG levels differences between HI and MM patients and between MGUS and MM patients were both significant (0.01 and 0.05 respectively). No relationship was found between MIP-1a or OPG levels and bone disease. However, there was a trend for longer survival in patients with MIP-1a or OPG levels lower than median (5-year overall survival 60 ± 12 vs 38 ± 14, p=0.08 and 66 ± 13 vs 29 ± 13, p=0.07 respectively). In addition MIP-1a levels were correlated with ISS stage: MIP-1a levels were 28.3±11.3 in ISS stage 1, 29.8±11.1 in ISS stage 2, 39±19.2 in ISS stage 3 (p=0.02). In conclusion, in our experience serum OPG levels are higher in MM patients than in MGUS or HI, MIP-1a levels are correlated with the ISS stage and both high serum MIP-1a and OPG levels at diagnosis are related with a shorter survival.


2019 ◽  
Vol 7 (3_suppl) ◽  
pp. 2325967119S0017
Author(s):  
Flo Edobor-Osula ◽  
Tamir Bloom ◽  
Ciaxia Zhao ◽  
Cornelia Wenokor ◽  
Sanjeev Sabharwal

What was the question? The purpose of this study was to evaluate the prevalence of OCD-like lesions around the knee in children with Blount disease. Additionally, we planned to describe the morphologic features of these OCD-like lesions based on plain radiographs and MRI and evaluate any clinical factors that may be associated with such radiologic findings How did you answer the question? After institutional review board approval, the medical records of all patients with a diagnosis of Blount disease (ICD-9 732.4) treated between January 2005 and March 2016 at a single institution were reviewed. All patients included in this study had an initial standing full-length anteroposterior mechanical axis radiograph and anteroposterior and lateral knee radiographs. MRI information was included when available. All patients noted to have an OCD-like lesion on an imaging study (x-ray and/or MRI) were identified and each such MRI was reviewed by three independent examiners, a musculoskeletal radiologist and two pediatric orthopedic surgeons. Each patient’s OCD-like lesion was graded according to two validated staging systems, as described by DiPaola and Hefti. Student t test for comparison of continuous variables and chi -square for categorical variables. Differences were considered statistically significant at p<0.05. What are the results? A total of 68 patients with Blount disease were identified. Five patients were excluded: two due to inadequate imaging, and three patients were adults at initial presentation. Of the 63 remaining patients (87 affected limbs) all had plain radiographs and 37 of these patients (53 limbs) also had an MRI. A total of 9 OCD-like lesions in 6 patients were identified on plain radiographs, with an overall prevalence of 10% (6/63) of patients and 10% (9/87) limbs. From the 37 patients (53 limbs) who had an MRI, 7/37 (19%) patients 10/53 (19% limbs)had the OCD-like lesion present on their MRI. All lesions were found in the posterior one third of the medial femoral condyle. The mean area of the lesion on plain imaging was 197.2 mm 2 (95%CI = 133.9 mm 2, 260.5 mm 2) and 163.0 mm2 (95%CI = 107.6,218.5) on MRI (p=0.36). Based on the Hefti classification there were 3 stage I, 2 stage II and 5 stage III lesions. Using the Dipaola system there were 4 stage I, 4 stage II and 2 stage III lesions. Comparing patients with an OCD-like lesion versus those without, there was no statistically significant difference between the groups in terms of early-onset versus late-onset disease (p=0.21), gender (p=0.23), mean age at imaging (p=.0.06) and laterality (p=0.07). Additionally, there was also no significant difference between the two groups in terms of mean MAD (63.3 mm vs 71.9 mm, p=0.39), mean mLDFA (91.3 degrees vs 89.7 degrees, p=0.43) and mean MPTA (71.7 degrees vs 71.8 degrees, p=0.95). What is your conclusion? OCD-like lesions in the medial femoral condyle can be seen in children with Blount disease. The overall prevalence of these lesions is around 10% based on plain radiographs and 19% based on MRI scans. Based on the numbers available, we were unable to demonstrate any associations between the presence of such OCD-like lesions and the patient’s age, gender or magnitude of varus deformity. Further research is needed to fully ascertain the etiology and natural history of these lesions in children with Blount disease. [Table: see text][Figure: see text][Figure: see text]


2019 ◽  
Vol 100 (5) ◽  
pp. 746-750
Author(s):  
M A Garashova

Aim. To study the severity (according to the stages at the time of diagnosis) of female genital cancer detected in postmenopausal women in Baku in 20162018. Methods. 306 postmenopausal women with various tumors of the reproductive system were examined. The average age of the examined women was 59.30.4 (4883) years. 166 (54.2%) out of 306 patients had malignant tumors of the genitalia including ovarian cancer (n=97), endometrial cancer (n=50), cervical cancer (n=13), uterine sarcoma (n=6). Clinical, functional, laboratory, radiological, and morphological studies were performed. For the analysis of the obtained digital data, discriminant analysis methods were applied. The rate (Р%) and its 95% confidence intervals (mp%) of ovarian and endometrial cancer of the postmenopausal period among female citizens of Baku were calculated. Statistical significance of the difference between the indicators in the groups was determined by Pearson 2-criterion. All calculations were performed in Excel 2013 and SPSS-20. Results. According to the data of the study, ovarian cancer in the postmenopausal period was diagnosed in 15.53.7% of females at stage I, in 8.22.8% at stage II, in 66.04.8% at stage III, in 10.33.1% at stage IV of the development of the tumor process. In 68.06.6% of patients with endometrial cancer in the postmenopausal period, the tumor was determined at stage I, in 30.06.5% of patients at stage II, and in 2.02.0% of patients at stage III of the development of the tumor process. On comparison of the stages at detection of ovarian and endometrial cancer, a significant difference between these two forms of malignant neoplasms was found for both stages I and III. Conclusion. Detection of genital tumors in postmenopausal women is characterized by the diagnosis of ovarian cancer mainly in the later stages of the disease (compared to endometrial cancer), which indicates the need to develop effective screening methods for earlier detection of this tumor process.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 46-47
Author(s):  
Anaïs Schavgoulidze ◽  
Valerie Lauwers-Cances ◽  
Aurore Perrot ◽  
Herve Avet-Loiseau ◽  
Jill Corre

Background In the era of personalized treatment in multiple myeloma, high-risk (HR) patients must be defined accurately more than ever. The International Myeloma Working Group (IMWG) recommends to use the Revised International Staging System (R-ISS) to identify HR patients. This score combines ISS, abnormal serum LDH level and 3 high risk chromosomal abnormalities (CA): del(17p), t(4;14) and t(14;16). However, with the advent of new tools in genomics, assessing only 3 abnormalities seems to be limited. Moreover, LDH level is impacted by various medical conditions; its relevance in the score is questionable. Aims The main purpose of our work was to assess the R-ISS on a multi-center cohort of transplant-eligible patients (1180 patients). To our knowledge, this is the first large scale study in Europe. Methods Data were collected from NDMM patients enrolled in 3 clinical trials implemented by the Intergroupe Francophone du Myélome. All patients were eligible to an intensive treatment. The overall survival (OS) and progression-free survival (PFS) curves were estimated using the Kaplan-Meier method and compared using the stratified log-rank test. The hazard ratio (HR) for progression or death were estimated by a multivariate Cox regression analysis adjusted for age, sex and therapy. Discrimination was assessed by the Harrell's concordance index (C-index) which estimates the proportion of all pairs of patients in whom prediction and outcome are concordant and takes values from 0.5 (no discrimination) to 1.0 (perfect discrimination). Results Altogether, 1180 patients with MM were analysed. Median age of our cohort was 58 years. The majority of patients (78%) received an intensive treatment followed by an autologous stem-cell transplantation (ASCT). Median follow-up was 94 months for OS. Forty-three percent of patients had ISS stage I, 39% had ISS stage II and 18% had ISS stage III. In the multivariable Cox model, the risk of death was increased for ISS stage II versus I (HR, 1.8; P &lt; 0.001), as well for R-ISS stage III versus I (HR, 2.1; P &lt; 0.001). Thirty percent of patients had R-ISS stage I, 62% had R-ISS stage II and 8% had R-ISS stage III. In the multivariable Cox model, the risk of death was 1.8 times higher for R-ISS stage II versus I and 3.0 times higher for R-ISS stage III versus I. Then we compared patients between their couple ISS/R-ISS. Thirty-one percent of the patients from ISS I were upgraded in R-ISS II; 55% of ISS III patients were reclassified in R-ISS II. Patients from the ISS I/R-ISS II couple didn't have a higher risk of progression (HR, 1.02; P = 0.893) or death (HR, 1.36; P = 0.115) than patients in the ISS I/R-ISS I subgroup. We also focused on the patients classified in R-ISS stage II (736 patients). We compared several subgroups: high risk CA (defined by R-ISS) versus standard risk, del(17p) vs. no del(17p), t(4;14) vs. no t(4;14) and high LDH vs. normal LDH. In the multivariable Cox model for OS, the risk of death was increased for patients with del(17p) (HR, 2.14; P &lt; 0.001), t(4;14) (HR, 2.06; P &lt; 0.001) and any of the high risk CA (HR, 2.15; P &lt; 0.001). Conversely, high LDH didn't have an impact neither on PFS (HR, 1.10; P = 0.333) nor OS (HR, 1.09; P = 0.540). Finally, we assessed the performance of the different prognostic models for discriminating patients who progressed from those who didn't (PFS) and patients who died from those who survived (OS) with the Harrell's C-index. The C-index for the R-ISS was the same than the ISS one for both PFS (0.56) and OS (0.61). R-ISS didn't give an additional prognostic value to the ISS. For every models, C-index were the same with or without LDH level; a LDH level upper than the upper limit of normal range didn't bring predictive gain on PFS or OS. C-index was better when we assessed each criteria of the R-ISS independently; this system presents the advantage of considering different prognostic weights and also different associations. Conclusion Our study confirms a significant difference for both PFS and OS between R-ISS stages I, II and III, but importantly, we show that the discriminatory ability of the R-ISS, assessed by the Harrell C-index, is equivalent to the ISS. Moreover, patients in stage R-ISS II have different prognosis depending on their cytogenetic while LDH level doesn't give any difference. Combining ISS, high risk CA and LDH level in only 3 categories induces a loss in the prognosis assessment. A model which assesses all the parameters in an independent way would be better. Figure 1 Disclosures Perrot: Amgen, BMS/Celgene, Janssen, Sanofi, Takeda: Consultancy, Honoraria, Research Funding.


2019 ◽  
Vol 23 (1) ◽  
pp. 153-158
Author(s):  
М. А. Shyshkin ◽  
V. A. Tumanskiy

Colorectal adenocarcinoma (CRA) is the result of numerous mutations accumulation. The aim of the work was to study KRAS gene transcriptional activity at I, II, III, and IV stages of CRA development and to analyze the correlations between KRAS and Ki-67, TP53, CDH1, CTNNB1 genes transcriptional activity. Pathohistological and molecular-genetic study of surgical material from 40 patients with CRA, as well as sectional material of 10 fragments of the distal colonic wall was conducted. The following statistical methods were used: descriptive statistics, χ2 test, Kruskal-Wallis test, Spearman’s rank correlation coefficient. It was established that CRA is characterized by increased KRAS transcriptional activity: Me of mRNA expression is 0.42 (0.36; 0.43) at stage I, 1.31 (1.09; 2.91) at stage II, 1.75 (1.31; 2.93) at stage III, and 2.91 (1.85; 3.50) at stage IV. Decreasing of Ki-67 gene transcriptional activity was revealed: Me of mRNA expression is 3.20 (2.31; 3.59) at stage I, 2.92 (1.80; 3.50) at stage II, 1,27 (1.19; 2.08) at stage III, and 0.52 (0.28; 1.04) at stage IV. As about TP53 gene, increasing of transcriptional activity was detected: Me is 2.15 (0.82; 2.30) at stage I, 2.80 (1.32; 4.50) at stage II, 3.80 (2.32; 6.50) at stage III, 7.80 (5.99; 8.92) at stage IV. Also, a direct medium correlation between the KRAS and TP53 transcriptional activity levels was revealed. There is a decreasing of CDH1 transcriptional activity: Me is 0.88 (0.42; 1.14) at stage I, 0.48 (0.23; 1.13) at stage II, 0.15 (0.09; 0.36) at stage III and 0.08 (0.04; 0.41) at stage IV. A reverse medium correlation between KRAS and CDH1 was revealed. The study of CTNNB1 gene mRNA at different stages of CRA indicated the absence of statistically significant difference: Me is 2.88 (2.38; 5.38) at stage I, 3.83 (2.59; 5.99) at stage II, 2.02 (1.38; 6.95) at stage III, and 2.27 (1.23; 2.93) at stage IV. So, KRAS gene transcriptional activity increases from I to IV stages in CRA, affecting apoptosis and adhesive properties of cancer cells.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2326-2326
Author(s):  
David C. Simpson ◽  
Jun Gao ◽  
Conrad V. Fernandez ◽  
Margaret Yhap ◽  
Victoria E. Price ◽  
...  

Abstract Hodgkin’s Disease (HD) is the most common lymphoma affecting young adults and teenagers. Bone marrow involvement is rare but if present, infers Stage IV disease and an inferior outcome. Adult studies have suggested that bone marrow examination (BME) may not be necessary unless certain risk factors are present. However, some pediatric centers continue to perform BME routinely on all children with HD. BME is invasive and generally performed under conscious sedation in children. We validated and administered an internet-based survey to examine the practice of all Canadian pediatric oncologists regarding BME in children with HD. We also retrospectively evaluated the impact of routine BME on the HD patients treated at our institution over the past 27 years. Forty-three percent of eligible physicians (n=93) completed the survey and 16 of a total of 17 Canadian pediatric oncology centers were represented. BME universally consisted of bilateral bone marrow aspirates and trephine biopsies. Routine BME for Stage III and IV disease was consistently practised nationally (by 92% and 97% of respondents, respectively). By contrast, 54% and 70% of respondents reported performing routine BME in low stage (Stage I and II) disease, respectively. Respondents were more likely to report performing routine BME in low stage patients, if their pediatric hematology/oncology training was entirely outside Canada (p=0.04 for Stage I and p=0.07 for Stage II) and if they practiced at smaller centers (p=0.05 for Stage I and p=0.03 for Stage II). There were no differences in practice regarding BME associated with the number of years in practice or the number of patients seen annually by the respondent. If not part of routine staging for all patients, BME was more likely performed if there were “B” symptoms, cytopenias, and/or bulky disease. Most respondents (95%) would proceed with BME following a positive PET scan. In the review of local institutional practice, 62 patients with HD and BME were eligible for analysis. Only 4 patients (6.5%) had a positive BME. No patient with otherwise low stage disease was found to have bone marrow involvement. Two patients, who would have been assigned as Stage III disease, were upstaged to Stage IV due to their BME. Comparison of staging with and without BME demonstrated no significant difference. Hemoglobin level was found to be the to be the only significant risk factor for marrow involvement based on univariate analysis(put in statisticp=0.006). Age, gender, histologic subtype, presence of “B” symptoms, and other blood parameters (white count, platelets, ESR and transaminases) were not significant factors. Practice regarding BME in children with low stage HD is highly variable across Canada. Bone marrow examination in pediatric patients with low stage HD should be abandoned, unless there is a specific indication to do so (for example positive PET scan or unexplained anemia). Moreover, BME does not appear to add any additional therapeutic direction for higher stage patients.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 88-88
Author(s):  
Francisca Ferrer-Marin ◽  
Ravi K. Gutti ◽  
Zhi-Jian Liu ◽  
Joseph Italiano ◽  
Zhongbo Hu ◽  
...  

Abstract Abstract 88 Thrombopoietin (Tpo) and its receptor (c-mpl) constitute the main regulatory axis of megakaryocyte (MK) proliferation and maturation. Accordingly, adult Tpo and c-mpl knockout (KO) mice exhibit an 85% reduction in MK concentration, although the residual 10–15% MKs are ultrastructurally normal. The phenotype of newborn Tpo or c-mpl KO mice has not been well characterized, but we and others have described substantial molecular differences between neonatal and adult megakaryocytopoiesis, including several pathways that mediate the high proliferative rate of neonatal MK progenitors. Recently, two groups reported neonates with c-mpl mutations associated with congenital amegakaryocytic thrombocytopenia, who in the neonatal period exhibited normal numbers of immature appearing marrow MKs. The fact that these infants were severely thrombocytopenic at that time suggests that their MKs did not produce platelets normally. These reports, coupled with our recent observation that Tpo mediates the cytoplasmic maturation of human neonatal MKs, led us to hypothesize that, during fetal and neonatal life, Tpo-independent pathways predominantly stimulate MK proliferation, while MK maturation is Tpo-dependent. To test this hypothesis, we studied the characteristics of MKs generated in vivo in neonates in the absence of c-mpl. Since we have previously demonstrated that the liver is the main site of megakaryocytopoiesis in newborn mice, we evaluated MKs in the livers of c-mpl KO and WT mice (both C57BL/6) on day of life 1 and 3. As a first step, we quantified MKs immunohistochemically stained with an anti-vWF antibody, and found that MKs in the liver of newborn c-mpl KO mice were reduced by approx. 70%. Next, we examined the ultrastructure of these liver MKs by transmission electron microscopy, and categorized c-mpl KO MKs (n=28) and WT MKs (n=32) as stage I (immature), stage II (abundant alpha-granules and a developing demarcation membrane system, DMS), or stage III (platelet producing MKs, with an open DMS). According to these criteria, 50% of WT MKs were stage II, and 50% were stage III. In contrast, 22% of c-mpl KO MKs were stage I, 57% were stage II, and only 21% were stage III. Furthermore, significant ultrastructural abnormalities were found in 70% of c-mpl KO MKs, including decreased numbers of platelet granules, a very disorganized appearing closed demarcation membrane system, and/or an abnormally wide peripheral zone. Since MKs in adult mice mature normally in the absence of Tpo, we then hypothesized that our findings reflected a downregulation of Tpo-independent pathway(s) mediating MK maturation in neonates. In that regard, we recently found that the microRNA miR9 was expressed at 10- to 14-fold higher levels in murine fetal and neonatal compared to adult MKs. Since CXCR4 (the receptor for SDF-1) is a predicted target of miR9, and in view of recent studies characterizing the role of the SDF-1/CXCR4 axis as a Tpo-independent pathway that stimulates MK maturation, we evaluated CXCR4 protein expression in cultured MKs derived from murine fetal liver (E13.5), newborn liver, and adult bone marrow, by Western Blot. As predicted, CXCR4 protein levels were significantly lower in fetal and neonatal compared to adult MKs (p=0.003). To evaluate the significance of these findings in humans, we then quantified miR9 and CXCR4 protein levels in cord blood-derived and adult peripheral blood-derived human MKs (n=3 per group). Consistent with the murine findings, we found that miR9 levels were approximately 20-fold higher and CXCR4 protein levels were significantly lower in human neonatal compared to adult MKs (p<0.05 for both). Finally, to determine whether miR9 regulates CXCR4 protein expression, Meg-01 cells were nucleofected with miR9 or Cy3 (control). As hypothesized, up-regulation of miR9 resulted in a significant reduction in CXCR4 protein levels compared to control cells (p=0.02). In conclusion, our findings indicate that MKs in the neonatal period do not mature normally in the absence of Tpo, presumably due to a deficiency in Tpo-independent pathway(s) of MK maturation at this developmental stage. Our data also identified a developmental downregulation of CXCR4 protein expression by miR9 in fetal and neonatal MKs. Given the role of the SDF/CXCR4 axis mediating Tpo-independent MK maturation, this provides a potential mechanism to explain the c-mpl KO findings. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 37 (4) ◽  
Author(s):  
Fatma Kaplan Efe

Objectives: We aimed to investigate whether Monocyte-to-HDL ratio (MHR) had an association with albuminuria in patients with diabetic nephropathy (DN). Methods: Diabetic patients, who had admitted to the outpatient clinic of general internal disease department between September 2017 - February 2018 and had their spot urinary albumin/creatinine ratio measured, were examined retrospectively. Patients were separated based on the presence of DN. Patients with DN were grouped as Stage-I, Stage-II and Stage-III chronic kidney disease (CKD). Groups were compared in terms of MHR. The presence of a correlation between MHR and albuminuria was investigated. Results: MHR was found to be higher in the DN (n=85) group compared to Non- DN group. (16.2±5.5 vs. 14.3±4, p=0.037) And there was no significant difference in Stage-I, Stage-II and Stage-III CKD groups in terms of MHR. (15.2± 3.4, 16.1±6.0, 17.1±6.0, p=0.485). No significant correlation was found between MHR and albuminuria in DN and non-DN groups (p=0.634, r=0.052; p=0.553, r=-0.059). Conclusions: DN group had higher MHR than non-nephropathy group, whereas, there was no correlation between albuminuria and MHR. doi: https://doi.org/10.12669/pjms.37.4.3882 How to cite this:Efe FK. The association between monocyte HDL ratio and albuminuria in diabetic nephropathy. Pak J Med Sci. 2021;37(4):---------.  doi: https://doi.org/10.12669/pjms.37.4.3882 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5580-5580 ◽  
Author(s):  
Elizabeth Kennedy-LeJeune ◽  
Hollis O'Neal ◽  
Lauren Miles ◽  
Diana Hamer ◽  
Vince D. Cataldo

Abstract Purpose: Multiple myeloma (MM), a cancer involving abnormal antibody production from plasma cells, accounts for approximately 1.8% of all new cancer cases in the US. The International Staging System (ISS) for MM classifies patients with serum beta2 microglobulin < 3.5mg/l and serum albumin ≥3.5g/dl as having stage I disease, patients with serum beta2 microglobulin ≥ 5.5 mg/l as having stage III disease, and all others as having stage II disease. The median survival by stage at time of diagnosis is 62 months, 45 months, and 29 months, respectively, for stages I, II, and III. The median age at time of diagnosis of MM is 69 years, with approximately 62% of all patients being at least 65 years old at time of diagnosis. There is a 2-fold increase in MM incidence amongst blacks as compared to whites in both the male and female population. This study was conducted to further characterize our MM patient population and to potentially identify racial and gender impact on mortality. Methods: A retrospective chart review of all patients in our geographic region diagnosed with MM between 2012 and 2017 was conducted using the Louisiana Tumor Registry Board database. Clinical data abstraction included epidemiology, laboratory, and pathologic data at time of diagnosis, and time to autologous stem cell transplant and death, if applicable. We performed chi-square analysis, linear regression, and survival analysis to compare survival outcomes between groups. Results: Chart review data was available for 184 of the 243 patients diagnosed with MM between 2012-2017, including 89 (47.6%) males and 98 females (52.4%), and 90 (48.1%) whites and 88 (47.1%) blacks. Females were significantly older than males (66.1 vs 62.6 years, p=0.037) at time of diagnosis yet whites were not significantly older compared to blacks (65.1 vs. 63.9 years, p=0.498). Among the 108 patients with documented stage of disease, 17 (15.7%) patients were diagnosed with stage I MM compared to 40 patients (37.0%) diagnosed at stage II and 51 (47.2%) diagnosed at stage III. With regards to stage, there was no significant difference between race or sex in our population. When adjusted for gender and age at diagnosis, race was a significant predictor of survival time with survival being 6.45 months shorter for black patients with MM compared to whites with the disease. (95% CI, 1.1 to 11.8; p = 0.019) Conclusion: Our data suggest that race exists as an independent predictor of shorter survival in our black patient population with MM. Additional studies investigating the biologic diversity of this disease are warranted to explain this racial disparity. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document